Loading
Life sciences · Journal article
Scientia Pharmaceutica · September 4, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of preclinical evidence examining how phenolic compounds modulate NF-κB, Nrf2, and STAT3 transcription factors in cancer animal models. The source identifies phenolic compounds as potential adjuncts to conventional therapy based on mechanistic studies but does not present clinical trial data or quantified clinical outcomes to support practice change.
Narrative review. Cancer animal models and preclinical studies; not human populations. Intervention: Phenolic compounds and their derivatives (unmodified molecules, semi-synthetic analogs, synthetic structures with natural pharmacophores).
Phenolic compounds are reported to have anticancer activity through modulation of inflammation and transcription factors in preclinical studies Phenolic compounds have been shown to synergize with conventional anticancer drugs, enhancing efficacy and reducing side effects Review highlights both therapeutic potential and limitations of phenolic compounds in cancer prevention and treatment
Phenolic compounds have been shown to synergize with conventional anticancer drugs, enhancing efficacy and reducing side effects
This review does not provide sufficient clinical evidence to guide treatment decisions. Clinicians should recognize that the reported synergy with conventional therapy and toxicity reduction remain mechanistic findings in animal models and require clinical validation before application to patient care.
This is a narrative review synthesizing preclinical evidence on mechanisms of phenolic compounds in cancer models, raising questions about therapeutic potential rather than answering them with clinical trial data.
As stated by the source record.
This review does not provide sufficient clinical evidence to guide treatment decisions. Clinicians should recognize that the reported synergy with conventional therapy and toxicity reduction remain mechanistic findings in animal models and require clinical validation before application to patient care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cancer is still one of the major causes of death globally. While there are many cancer therapies, they often come with significant adverse effects and limitations. A lot of studies have shown that using natural products can improve the efficacy of conventional therapies and decrease their toxicity. Natural products and their derivatives encompassing unmodified molecules, semi-synthetic analogs, and synthetic structures featuring natural pharmacophores, represent a major foundation for approved anticancer agents. Phenolic compounds are a large family of naturally occurring compounds found in plants and have attracted a lot of attention for their potential anticancer properties. Preclinical studies have shown that phenolic compounds have anticancer activity through different mechanisms, mainly by modulating inflammation, which plays a critical role in cancer development. Inflammatory processes in cancer involve complex molecular mechanisms regulated by both oncogenic and tumor-suppressing transcription factors. This review focuses on how phenolic compounds regulate transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), and signal transducer and activator of transcription 3 (STAT3), which are critical in cancer-related gene expression, ultimately leading to the inhibition of cancer cell proliferation, invasion, and metastasis. Furthermore, phenolic compounds have been shown to synergize with conventional anticancer drugs, enhancing their efficacy and reducing side effects. This review investigates the role of phenolic compounds in regulating transcription factors in cancer animal models, highlighting both the therapeutic potential and limitations of these compounds in cancer prevention and treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.